BlackRock Unit Reports 5.4% Passive Stake In Enanta, Or 1,560,091 Shares
The position in the Watertown drug developer is held for ordinary business, not to influence control, BlackRock certified.
BlackRock Portfolio Management holds 1,560,091 shares of Enanta Pharmaceuticals, or 5.4% of the common stock, according to a passive ownership filing (a Schedule 13G) made Tuesday. The position was measured as of September 30, and BlackRock certified it is not held to change or influence control of the company.
Voting power and the BlackRock units
BlackRock Portfolio Management has sole voting power over 1,461,051 of the shares and no shared voting power, the filing shows. It is classified as a parent holding company.
The filing reflects holdings of certain BlackRock business units rather than the whole firm. An exhibit lists those units, including BlackRock Fund Advisors, Aperio Group and BlackRock Institutional Trust Company.
Various persons have the right to receive dividends or sale proceeds from the stock, the filing says, and no one person's interest exceeds 5% of the outstanding shares.
A royalty earner with an RSV bet
Enanta, which discovers small molecule drugs for virology and immunology, earns royalties on AbbVie's hepatitis C treatment MAVYRET, built on glecaprevir, a drug Enanta discovered. As of September 30, 2025, it held $188.9 million in cash, cash equivalents and short-term marketable securities. Its market value was about $350 million in Tuesday trading.
On Monday the company said the first patient was dosed in RESOLVE, a Phase 2b/3 trial of its RSV antiviral zelicapavir in high-risk adults. Enanta expects topline data from the Phase 2b portion in 2027, and Phase 2b readouts from the pediatric LOTUS trial are also expected in 2027.
Enanta's next scheduled data points are the 2027 Phase 2b readouts from RESOLVE and LOTUS.
Sources
- SCHEDULE 13G — BlackRock Portfolio Management LLC re: ENANTA PHARMACEUTICALS INC (ENTA) — SEC EDGAR
- SCHEDULE 13G Exhibit 99 — EXHIBIT 99: ITEM 7 — SEC EDGAR
- Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV) – Company Announcement - FT.com — Financial Times